ArticleClinical transplantation2025
Protocol Biopsies in Delayed Graft Function Kidney Transplants From Brain-Dead Donors.
Article in Clinical transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Machine Learning-Assisted FTIR Spectroscopy Analysis of Kidney Preservation Fluids for Delayed Graft Function Risk Stratification.Journal of clinical medicine · 2026Article
- Findings and significance of early follow-up biopsies after treatment of acute rejection in kidney transplant recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Association between delayed graft function and cytomegalovirus infection after renal transplant.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDelayed graft function (DGF) is a significant challenge in deceased donor kidney transplantation, impacting approximately one third of patients and is associated with acute rejection. Post-transplant acute rejection is monitored in kidneys with DGF through sequential protocol biopsies in 7-10-day intervals, according to guidelines based on research done before the current era of immunosuppression treatment. As acute rejection rates have decreased, there is a need to reevaluate the rationale of protocol biopsies.
methodsWe studied the histology of all biopsies taken during the first month post-transplant among recipients of brain-dead donor kidneys with DGF at our institution during 2006-2023. All recipients received corticosteroids as induction. Anti-thymocyte globulin was additionally administered to 3% and 18% receive basiliximab.
resultsA total of 1022 biopsies were studied from 678 recipients. Of the 678 recipients, 178 (26%) had rejection. Most acute rejection episodes occurred 7-10 days post-transplant. In case of no rejection in the first biopsy, rejection was found in 10% of the cases with subsequent biopsies. No risk factors for acute rejection in these later biopsies could be identified in regression analysis. The presence of donor-specific human leukocyte antibodies was associated with higher rates of antibody-mediated rejection during the first post-transplant month (20% vs. 1.3%, p < 0.001).
conclusionsThe first biopsy post-transplant in DGF kidneys has an important role in identifying early acute rejection. Of the patients with no rejection in the first biopsy, only 10% had a rejection in the second biopsy. Cases with borderline findings progressed to rejection in approximately one third of the cases. These data reflect the rate of early TCMR in deceased donor kidney transplants when 79% of patients did not receive an anti-T cell induction antibody.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.